BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Slieker MG, Deckers-kocken JM, Uiterwaal CSPM, van der Ent CK, Houwen RHJ. Risk factors for the development of cystic fibrosis related liver disease. Hepatology 2003;38:775-6. [DOI: 10.1053/jhep.2003.50403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 van der Doef HP, Kokke FT, van der Ent CK, Houwen RH. Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation. Curr Gastroenterol Rep. 2011;13:265-270. [PMID: 21384135 DOI: 10.1007/s11894-011-0185-9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
2 Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009;302:1076-83. [PMID: 19738092 DOI: 10.1001/jama.2009.1295] [Cited by in Crossref: 189] [Cited by in F6Publishing: 149] [Article Influence: 14.5] [Reference Citation Analysis]
3 Slieker MG, van der Doef HP, Deckers-Kocken JM, van der Ent CK, Houwen RH. Pulmonary prognosis in cystic fibrosis patients with liver disease. J Pediatr 2006;149:144; author reply 144-5. [PMID: 16860146 DOI: 10.1016/j.jpeds.2005.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12:116-124. [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
5 Leung DH, Yimlamai D. The intestinal microbiome and paediatric liver disease. Lancet Gastroenterol Hepatol 2017;2:446-55. [PMID: 28497760 DOI: 10.1016/S2468-1253(16)30241-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
6 Witters P, De Boeck K, Dupont L, Proesmans M, Vermeulen F, Servaes R, Verslype C, Laleman W, Nevens F, Hoffman I, Cassiman D. Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. J Cyst Fibros 2009;8:392-9. [PMID: 19733131 DOI: 10.1016/j.jcf.2009.08.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
7 Colombo C, Battezzati PM. Liver involvement in cystic fibrosis: primary organ damage or innocent bystander? J Hepatol 2004;41:1041-4. [PMID: 15582140 DOI: 10.1016/j.jhep.2004.10.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
8 Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 2021:S0168-8278(21)02115-2. [PMID: 34678405 DOI: 10.1016/j.jhep.2021.09.042] [Reference Citation Analysis]
9 Bhardwaj S, Canlas K, Kahi C, Temkit M, Molleston J, Ober M, Howenstine M, Kwo PY. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol. 2009;43:858-864. [PMID: 19525864 DOI: 10.1097/mcg.0b013e31819e8bbd] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
10 Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013;Jun 13; Epub ahead of print. [PMID: 23769887 DOI: 10.1016/j.prrv.2013.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
11 Brazova J, Sismova K, Vavrova V, Bartosova J, Macek M Jr, Lauschman H, Sediva A. Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin Immunol 2006;121:350-7. [PMID: 17052957 DOI: 10.1016/j.clim.2006.08.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
12 Corbett K, Kelleher S, Rowland M, Daly L, Drumm B, Canny G, Greally P, Hayes R, Bourke B. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr 2004;145:327-32. [PMID: 15343185 DOI: 10.1016/j.jpeds.2004.05.051] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
13 Boëlle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2019;69:1648-56. [PMID: 30058245 DOI: 10.1002/hep.30148] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
14 Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, Sokol RJ, Zemanick E, Accurso F, Hoffenberg EJ, Narkewicz MR. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One 2015;10:e0116967. [PMID: 25658710 DOI: 10.1371/journal.pone.0116967] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]